Notice Number: NOT-DA-16-043

Key Dates
Release Date: October 14, 2016

Issued by
National Institute on Drug Abuse (NIDA)
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP/CDC)

Purpose

The purpose of this Notice is to correct responsiveness criteria for applications submitted to RFA-DA-17-023 "Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24)”.

Part 2. Section I. Funding Opportunity Description

Specific Topics of Research Interest 

Current Language
Applications including the following types of studies will be considered non- responsive and will not be reviewed:

• Phase III clinical trials
• Cohort studies
• Studies of communities outside the United States or its territories
• Studies whose aims are not focused on the areas identified by the FOA
• Studies that do not include collaboration with a state or local health department, as evidenced by a letter of support and description of collaborative activities in the application
• Studies not focused on rural communities
• Studies that do not include collaboration with a state or local substance abuse agency

New Language:
Applications including the following types of studies will be considered non- responsive and will not be reviewed:

• Phase III clinical trials
• Cohort studies
• Studies of communities outside the United States or its territories
• Studies whose aims are not focused on the areas identified by the FOA
• Studies that do not include collaboration with a state or local health department, as evidenced by a letter of support and description of collaborative activities in the application
• Studies not focused on rural communities

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Richard A. Jenkins PhD
National institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: [email protected]